All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Can lenalidomide maintenance be given to patients with MM and COVID-19 infection?

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University, Ankara, TR. We asked, Can lenalidomide maintenance be given to patients with MM and COVID-19 infection?

Can lenalidomide maintenance be given to patients with MM and COVID-19 infection?

Beksaç provides an overview of the outcomes for patients with concurrent multiple myeloma and COVID-19 infection who received lenalidomide compared with patients who did not receive lenalidomide. These outcomes included the rate of severe COVID-19 infection and fatality.

Share: